gastroparesis from tirzepatide vs. Side Effects: What to Know gastroparesis and tirzepatide A 32-year-old

Tirzepatide, which combines the effects of glucose-dependent insulinotropic polypeptide and GLP-1, is undergoing phase 3 research for obesity treatment

Nutrients, 9 (12), 1286

These findings add to the growing need for improved tolerability of weight loss solutions to help people not only lose weight but keep their weight off by acting in a fast-onset, short-duration manner with very high tolerability. -- Session: Poster Presentation -- Date/Time: Tuesday, November 4, 2025 | 7:30 p.m

What should you know before considering microdosing

Recurrent ischaemic colitis associated with pseudoephedrine use

Jayne Chacko NBC Connecticut #CTHealthNews #WeightLossDrugs #FDA #ObesityMedicine #PatientSafety FDA Warns Against Unapproved #Retatrutide Versions Doctors are warning patients against using unapproved versions of #retatrutide, an experimental Eli Lilly and Company #weightloss #drug still in #clinicaltrials